Protalix Biotherapeutics, Inc. Announces Proposed $60 Million Offering of Convertible Notes

Published: Sep 12, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CARMIEL, Israel, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that it intends, subject to market conditions, to offer and sell $60 million principal amount of its convertible notes due 2018 (the "notes") through a private offering. The Company expects to grant the initial purchaser an option to purchase up to an additional $9 million principal amount of notes, exercisable for 30 days after the pricing date of the notes offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Help employers find you! Check out all the jobs and post your resume.

Back to news